Dental amalgams
This article was originally published in The Gray Sheet
Executive Summary
FDA is in the process of reviewing over 750 comments relating to the proposed reclassification of dental amalgams, CDRH Director David Feigal testifies during Nov. 14 hearing before the House Government Reform Committee. Earlier this year, FDA reopened the comment period for a Feb. 20 proposed rule that would classify encapsulated amalgam and dental mercury as Class II (1"The Gray Sheet" July 22, 2002, p. 10). FDA, NIH and CDC plan further review of 1993 findings showing no definitive evidence linking the placement of amalgams to onset of systematic disease, according to Feigal...